Chronic Hepatitis C
Good management of hepatitis C requires thorough pretreatment evaluation
Published in Blood Weekly, June 3rd, 2004
"Chronic hepatitis C virus infection is a common and serious disease. Although an estimated 2.7 million persons in the United States have this disease, most have not yet been diagnosed," scientists in the United States report.
"Recent advances in treatment provide successful cure in 50 to 80 percent of cases. Current drug therapy consists of a combination of pegylated interferon and ribavirin. Although all patients with chronic hepatitis C virus infection are potential candidates for treatment, pharmacologic therapy has a number of contraindications. Evaluation of suitability...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-06-03)
More Articles from Blood Weekly
- Blood Banking
Prestorage plasma filtration activates the complement cascade - Retrovirus
Human T-lymphotropic virus type 1 can spread directly between lymphocytes - Stem-Cell Research
Blastocyst-derived cell is source of neural derivates for differentiation study - Stem-Cell Research
Direct cell contact influences fate of bone marrow mesenchymal stem cells - Stem-Cell Research
Human neural progenitor cells possible source for treatment of Parkinson disease - Addiction Medicine
Family history predicts alcohol relapse after liver transplantation - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
